We and our community partners are continuing to fight for cabotegravir long-acting injectable (CAB-LA) access for our communities. Since our initial meeting in February and the release of our previous statements (March 1st; March 17th), no meaningful steps, including the issuance of a voluntary generic license by ViiV Healthcare, has taken place to ensure generic […]

Read the community’s response to ViiV’s recent actions Here As a community, we still strongly feel that key demands in our first letter went largely unanswered. This has left many of us concerned that without robust, transparent, and consultative actions by ViiV/GSK, access to CAB-LA will be delayed even further, prolonging the AIDS epidemics in […]

Join us on February 17th, 1-2.30 pm Dakar, 3-4.30 pm Johannesburg, 4-5.30 pm Nairobi. Register Here:  https://bit.ly/Long-Acting-Webinar Long-acting technologies have the potential to transform HIV prevention. One such technology is Cabotegravir, a long-acting injectable (known as CAB-LA) that was recently approved in the US. CAB-LA offers a safe, highly effective HIV prevention option without the […]

Please read the full statement here: Darunavir/ritonavir (DRV/r) is a highly effective and well-tolerated protease inhibitor that has been used to treat people living with HIV (PLHIV) for over a decade. Though DRV/r has seen significant utilization in many high-income settings, this has not been the case in low- and middle-income countries (LMICs) despite DRV/r’s […]

Please plan to join our second webinar on Diagnostics in our ongoing series and be ready to participate as your feedback and input will be incredibly valuable. We recommend reviewing the discussion questions ( displayed at the bottom of the flier) in advance to ensure rich discussions. Kindly share widely amongst your networks.

Community representation is critical at the national and global decision-making levels, particularly for the formulation of policies and guidelines and in response to updated clinical data. AFROCAB invited Communities to participate in a community meeting on weight gain and hyperglycemia with use of ARVs. The meeting included community representatives from approximately 20 countries to formally document the community perspective […]

Everyone who starts HIV treatment in lower- and middle-income countries should start treatment with a combination containing dolutegravir, the World Health Organization (WHO) announced at the 10th International AIDS Society Conference on HIV Science (IAS 2019) in Mexico City this past July. The new recommendations are intended to settle uncertainty over whether women of childbearing […]